Skip to content

    Melanoma/Skin Cancer Health Center

    Font Size
    A
    A
    A

    Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage II Melanoma Treatment

    continued...

    Clinicians should be aware that the high-dose regimens have significant toxic effects.

    Evidence (high-dose interferon alpha-2b):

    1. A multicenter, randomized, controlled study (EST-1684) compared a high-dose regimen of interferon alpha-2b (20 mU/m2 of body surface per day given intravenously 5 days a week for 4 weeks, then 10 mU/m2 of body surface per day given subcutaneously 3 times a week for 48 weeks) with observation.[8][Level of evidence: 1iiA]
      • This study included 287 patients at high risk of recurrence after potentially curative surgery for melanoma (patients with melanomas thicker than 4 mm without involved lymph nodes or patients with melanomas of any thickness with positive lymph nodes).
      • Patients who had recurrent melanoma involving only the regional lymph nodes were also eligible.
      • At a median follow-up of 7 years, this trial demonstrated a significant prolongation of RFS (P = .002) and OS (P = .024) for patients who received high-dose interferon.
      • The median OS for patients who received the high-dose regimen of interferon alpha-2b was 3.8 years, compared with 2.8 years for those in the observation group.
      • A subset analysis of the stage II patients failed to show any RFS or OS benefit from high-dose interferon. Because the number of stage II patients was small in this subset analysis, it is difficult to draw meaningful conclusions from this study for this specific group.
    2. A multicenter, randomized, controlled study (EST-1690) conducted by the same investigators compared the same high-dose interferon alpha regimen with either a low-dose regimen of interferon alpha-2b (3 mU/m2 of body surface per day given subcutaneously 3 times per week for 104 weeks) or observation. The stage entry criteria for this trial included patients with stage II and III melanoma. This three-arm trial enrolled 642 patients.[9][Level of evidence: 1iiA]
      • At a median follow-up of 52 months, a statistically significant RFS advantage was shown for all patients who received high-dose interferon (including the clinical stage II patients) when compared with the observation group (P = .03).
      • No statistically significant RFS advantage was seen for patients who received low-dose interferon when compared with the observation group.
      • The 5-year estimated RFS rate was 44% for the high-dose interferon group, 40% for the low-dose interferon group, and 35% for the observation group.
      • Neither high-dose nor low-dose interferon yielded an OS benefit when compared with observation (HR, 1.0; P = .995).
    1 | 2 | 3 | 4
    Next Article:

    Today on WebMD

    Malignant melanoma
    How to spot it early.
    Woman checking out tan lines
    There’s a dark side to that strive for beauty.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    12 Ways to Protect Your Skin from Melanoma
    ARTICLE
    precancerous lesions slideshow
    SLIDESHOW
     
    Do You Know Your Melanoma ABCs
    VIDEO
    15 Cancer Symptoms Men Ignore
    ARTICLE
     
    screening tests for men
    SLIDESHOW
    Vitamin D
    SLIDESHOW
     
    Is That Mole Skin Cancer
    VIDEO
    Brilliant sun rays
    Quiz